Direct Answer
IDEXX Laboratories is the global leader in veterinary diagnostics, generating recurring high-margin revenue from proprietary consumables used in its installed base of over 130,000 point-of-care diagnostic instruments in veterinary clinics worldwide, alongside a large reference laboratory network.
IDEXX Laboratories (IDXX): Veterinary Diagnostics and Point-of-Care Testing
Company Snapshot
| Ticker | IDXX |
|---|---|
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Health Care Equipment |
| Headquarters | Westbrook, Maine |
| Founded | 1983 |
| CEO | Jay Mazelsky |
| Revenue (FY2024) | ~$3.9 billion |
| CIK | 0000874716 |
| Index membership | S&P 500 |
What Does IDEXX Laboratories Do?
IDEXX Laboratories develops and commercializes diagnostic products and services for the companion animal veterinary market, as well as food and water safety testing. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX has grown into the global leader in veterinary diagnostics through a combination of organic innovation and strategic expansion of its reference laboratory network.
The core of IDEXX's business is selling diagnostic instruments to veterinary clinics (point-of-care analyzers for blood chemistry, hematology, urinalysis, immunoassay, and imaging) and then generating recurring revenue from the proprietary reagents, cartridges, and test kits those instruments require. Veterinarians use these tools to diagnose conditions, monitor treatment, and screen healthy animals at wellness visits.
IDEXX also operates the world's largest network of reference veterinary laboratories, providing more complex or specialized testing when results from in-clinic analyzers are insufficient or when specialized expertise is needed. The reference lab business connects directly to clinics through IDEXX's VetConnect PLUS practice information system, integrating diagnostic results into patient records.
Business Segments
IDEXX operates through three segments:
- Companion Animal Group (CAG): Point-of-care instruments and consumables, reference laboratory testing, practice management software (Cornerstone), and digital imaging systems for veterinary clinics. Roughly 90% of total revenue.
- Water: Colilert and related products for testing drinking water and wastewater for bacterial contamination, sold to municipalities and utilities globally. Roughly 4-5% of revenue.
- Livestock, Poultry, and Dairy (LPD): Diagnostics for food-producing animals and food safety testing. Roughly 5-6% of revenue.
The Installed Base and Recurring Revenue Model
IDEXX's commercial strategy centers on building an installed base of proprietary diagnostic instruments in veterinary clinics and then monetizing that base through recurring consumable sales. The company has placed over 130,000 instruments globally, creating a large, captive revenue stream that grows as the installed base expands and as veterinarians run more tests per visit.
IDEXX's Catalyst chemistry analyzer, ProCyte hematology analyzer, and SNAP rapid test platforms are embedded in the workflow of hundreds of thousands of veterinary practices. Each platform uses proprietary consumables -- slides, cartridges, reagents -- that must be purchased exclusively from IDEXX. Annual revenue per instrument location compounds as testing volumes increase and as IDEXX introduces additional test types on existing platforms.
The VetConnect PLUS software creates additional stickiness by integrating point-of-care and reference lab results into a unified patient record, making IDEXX the digital backbone of many practices' diagnostic workflow.
Reference Laboratory Network
IDEXX operates veterinary reference laboratories across the United States, Europe, Asia-Pacific, and other international markets. The reference lab business complements point-of-care diagnostics by providing testing that is too complex, infrequently needed, or expensive to perform in-clinic.
Scale is a competitive advantage in reference labs: a larger network enables faster sample transport and turnaround times, supports a broader test menu, and allows investment in specialized technology and expertise that smaller competitors cannot match. IDEXX's reference labs process millions of samples per year, generating revenue from a per-test fee model that is largely independent of instrument placement.
Frequently Asked Questions
How does IDEXX Laboratories make money?
IDEXX earns revenue through three segments: Companion Animal Group (CAG, roughly 90% of revenue, veterinary diagnostics including point-of-care analyzers, consumables, reference laboratory testing, and practice management software for veterinary clinics), Water (roughly 4-5%, testing products for drinking water safety), and Livestock, Poultry, and Dairy (LPD, roughly 5-6%, diagnostics and food safety testing). CAG is subdivided into recurring consumable/service revenues (reference lab work, consumable test kits, and subscriptions) and instrument placements. The recurring portion generates most of IDEXX's high-margin revenue.
What is IDEXX's razor-and-blades business model?
IDEXX places diagnostic analyzers (the equivalent of the razor) in veterinary clinics, often at low cost or on reagent rental agreements, and generates ongoing high-margin revenue from the proprietary consumables (reagents, cartridges, slides) those instruments require. Veterinary practices become operationally dependent on the IDEXX platform, and switching to a competing analyzer system is disruptive because it requires staff retraining, validation, and often upfront capital. IDEXX's installed base of over 130,000 instruments worldwide generates recurring consumable revenue with high retention rates, giving the company predictable growth even without new customer acquisition.
How has pet ownership growth driven IDEXX's performance?
Long-term growth in companion animal ownership and spending has been a secular tailwind for IDEXX. Americans have increasingly treated pets as family members, leading to higher veterinary visit rates, more willingness to spend on diagnostics and treatment, and growth in pet insurance adoption that reduces price sensitivity. Pet ownership surged during COVID-19 as millions of new households acquired pets, creating a structural increase in the addressable market for veterinary services. IDEXX benefits not only from more pets but also from diagnostic penetration: the share of veterinary visits that include point-of-care or reference lab testing has grown as diagnostic technology improves and veterinarians recognize testing's clinical value.
What are IDEXX's main competitors?
IDEXX competes primarily with Zoetis (which sells diagnostics through its Vetscan line) and Heska (now part of Mars Petcare's veterinary division) in point-of-care instruments, and with Antech Diagnostics (owned by Mars) and VCA Animal Hospitals' labs in reference laboratory services. IDEXX holds an estimated 50-60% market share in veterinary point-of-care diagnostics and operates the largest network of veterinary reference laboratories globally. Its scale advantage in reference labs creates faster turnaround times and broader test menus than competitors can match, reinforcing its position despite pricing competition.
What are the main risks for IDEXX investors?
Key risks include: valuation sensitivity given IDEXX's historically high price-to-earnings multiples that require sustained growth to justify; veterinary clinic capacity constraints limiting how many visits (and thus diagnostics) occur; competition from Zoetis, Heska, and Antech; economic sensitivity as pet owners may defer elective veterinary visits in recessions; geographic expansion risk as international markets have lower diagnostic penetration but also different regulatory and competitive dynamics; and the structural risk that veterinary chains (consolidating rapidly through private equity) might negotiate lower pricing as they gain purchasing scale.